#United States #New York #Class Action #Pomerantz LLP #Organogenesis Holdings

Pomerantz Law Firm Investigates Organogenesis Holdings Inc. Claims

New York, January 22, 2026 — The Pomerantz Law Firm has initiated an investigation into potential claims on behalf of investors in Organogenesis Holdings Inc. (NASDAQ: ORGO). This probe comes in response to reports suggesting that certain executives and directors of the company may have engaged in unlawful business practices, including securities fraud.

Background on the Investigation

The firm urges any stakeholders who feel they have suffered financial loss due to these actions to contact attorney Danielle Peyton at Pomerantz LLP. The investigation is particularly relevant following a recent announcement from the Centers for Medicare and Medicaid Services (CMS). On December 26, 2025, CMS revealed its decision to withdraw final Local Coverage Determinations (LCDs) concerning skin substitute grafts and other cellular and tissue-based products. This regulatory change significantly impacts Organogenesis, as analysts predict heightened competition from over 300 other companies in the market without those protections.

Consequently, Organogenesis's stock took a hit, dropping $0.59 per share, marking a decline of 10.14%. The closing price on December 30, 2025, was registered at $5.28 per share. This steep decline has raised concerns among investors, prompting the legal firm to take swift action.

About Pomerantz Law Firm

Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation. The firm was established over 85 years ago by the late Abraham L. Pomerantz, who is celebrated as a pioneer in the field of securities class actions. With offices in major cities including New York, Chicago, Los Angeles, and several international locations, Pomerantz has a reputation for securing multimillion-dollar recoveries for class members affected by securities fraud and other corporate misconduct.

The firm's long-standing dedication to advocacy for victims' rights remains paramount, as they continue to uphold the legacy of integrity and justice set forth by its founder. For further information regarding joining this class action or to inquire about specific details, investors can contact Danielle Peyton directly.

Conclusion

As the situation develops, it is vital for investors in Organogenesis Holdings Inc. to stay informed about potential legal recourse and the implications of regulatory changes affecting their investments. The Pomerantz Law Firm stands ready to assist and represent the interests of impacted shareholders during this challenging time.

For inquiries or to participate in the investigation, reach out to Danielle Peyton at Pomerantz LLP via email at [email protected] or call at 646-581-9980, extension 7980.